Over the past two decades, the landscape of CLL therapy has undergone a significant transformation, moving away from chemoimmunotherapy approaches towards the adoption of targeted therapies, notably BTK and B-cell lymphoma 2 inhibitors [10, 40]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.